Left panel, mutation frequency as a function of the indicated T/G or T/G with a SSB.
Bottom panels: mutations detected in Sanger sequenced yeast clones unmodified or harbouring a chimeric YBR194W-snR6 locus.
Our findings suggest that this novel mutation should be incorporated into the panel of mutations analysed in high-risk families of the appropriate ethnic background, and that the repertoire of BRCA1 mutations in Jewish high-risk families may be limited, regardless of ethnic origin.
For this analysis, we defined negative as those samples that proved to be negative for the panel of mutations, i.e., BRAF V600E, NRAS Q61R, IDH1 mutations and RET/PTC rearrangements.
A panel of mutations was introduced into residues substantially displaced upon the G93A mutation.
The panel of mutations contained, among others, the most prevalent mutant CBS alleles to well represent the molecular mechanisms relevant for the majority of patients suffering from CBS deficiency.
Commercially available CF carrier screening panels offer a limited panel of mutations, however, making them insufficiently sensitive for certain groups within an ethnically diverse population.
The panel of mutations and variants was tested against 386 blinded samples supplied by "authority" laboratories highly experienced in cystic fibrosis transmembrane regulator genotyping; >98% concordance was observed.
A preclinical positron emission tomography (PET) study was performed in mice bearing NSCLC xenografts with a representative panel of mutations: an EGFR-WT xenograft cell line (A549), an acquired treatment-resistant L858R/T790M mutant (H1975), and a treatment-sensitive exon 19 deleted mutant (HCC827).
Using sucrose gradients to sub-fractionate mitochondrial extracts, we demonstrated that indeed wild type PINK1 exists in protein complexes that fractionate with respiratory chain complexes I, II, III, IV, (Figure 4B, top panel) and mutations in PINK1 do not alter the localization of the protein within the multi-protein complexes (Figure 4B, 2nd and 3rd panels).
